产品
编 号：F431865
产品类型
规格
价格
是否有货
1mg
询价
询价
5mg
询价
询价
10mg
询价
询价
结构图
CAS No: 705287-60-1
产品详情
生物活性：
Stamulumab (MYO-029) is a recombinant human IgG1λ antibody that binds to myostatin and neutralizes its activity by preventing binding to its endogenous high-affinity receptor ActRIIB. Stamulumab leads to muscle fiber hypertrophy and not hyperplasia in SCID mice. Stamulumab has the potential for Becker muscular dystrophy (BMD), facioscapulohumeral dystrophy (FSHD), and limb-girdle muscular dystrophy (LGMD) research.
体内研究：
Stamulumab (MYO-029; 腹腔给药; 1-10 mg/kg/周; 持续 12 周) 在 SCID 小鼠体内以浓度依赖性方式增加骨骼肌质量。Stamulumab 导致肌纤维肥大而不是增生。Stamulumab (静脉注射; 1, 5, 20, 100 mg/kg/周; 持续 4 周) 在 C57/SCID 小鼠中的中心清除率 (CL) 为 0.25 mL/h/kg.Pharmacokinetic Parameters of Stamulumab (MYO-029).C57/SCID mice IV (1-100 mg/kg/week for 4 weeks) Sprague Dawley rats (2-50 mg/kg; single injection) Cynomolgus monkeys (10-100 mg/kg/week for 5 or 39 weeks)
CL (mL/h/kg)0.2450.5420.228
Volume of central compartment (mL/kg)10358.941.8
Distributive clearance (mL/h/kg)1.790.815
Animal Model:Female SCID mice
Dosage:1, 2.5, 5, 10 mg/kg
Administration:IP; every week for 12 weeks
Result:Increased skeletal muscle mass in vivo in a concentration‐dependent manner.
Stamulumab (MYO-029) is a recombinant human IgG1λ antibody that binds to myostatin and neutralizes its activity by preventing binding to its endogenous high-affinity receptor ActRIIB. Stamulumab leads to muscle fiber hypertrophy and not hyperplasia in SCID mice. Stamulumab has the potential for Becker muscular dystrophy (BMD), facioscapulohumeral dystrophy (FSHD), and limb-girdle muscular dystrophy (LGMD) research.
体内研究：
Stamulumab (MYO-029; 腹腔给药; 1-10 mg/kg/周; 持续 12 周) 在 SCID 小鼠体内以浓度依赖性方式增加骨骼肌质量。Stamulumab 导致肌纤维肥大而不是增生。Stamulumab (静脉注射; 1, 5, 20, 100 mg/kg/周; 持续 4 周) 在 C57/SCID 小鼠中的中心清除率 (CL) 为 0.25 mL/h/kg.Pharmacokinetic Parameters of Stamulumab (MYO-029).C57/SCID mice IV (1-100 mg/kg/week for 4 weeks) Sprague Dawley rats (2-50 mg/kg; single injection) Cynomolgus monkeys (10-100 mg/kg/week for 5 or 39 weeks)
CL (mL/h/kg)0.2450.5420.228
Volume of central compartment (mL/kg)10358.941.8
Distributive clearance (mL/h/kg)1.790.815
Animal Model:Female SCID mice
Dosage:1, 2.5, 5, 10 mg/kg
Administration:IP; every week for 12 weeks
Result:Increased skeletal muscle mass in vivo in a concentration‐dependent manner.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备